Abstract
Novel biomarkers for screening, diagnosis and monitoring the treatment of nasopharyngeal carcinoma (NPC), one of the most common cancers in Vietnam, are urgently required. Increasing evidence suggests that microRNA-141 (miR-141) is associated with NPC, owing to its ability to affect the expression of genes that modulate tumorigenesis. Unfortunately, research on miR-141 expression in Vietnamese patients is limited. Therefore, the objective of the current study was to evaluate miR-141 expression and assess whether miR-141 might be a potential biomarker for diagnosis of NPC in Vietnamese patients. Total RNA isolated from 40 NPC biopsy samples and 37 non-cancerous samples was analyzed by quantitative reverse-transcription PCR. The miR-141 expression levels were compared between NPC biopsy and non-cancerous samples. The frequency of miR-141 detection was 37.50% and 10.80% in the NPC and non-cancerous samples, respectively (p = 0.0143). The miR-141 expression was 5.27 times higher in tumor samples than non-cancerous samples. Additionally, the RR (Relative risk) and OR (Odds ratio) were 1.83 (95%CI = 1.2576-2.6675, p = 0.0016) and 4.95 (95%CI = 1.4625-16.7541, p = 0.01), respectively. In conclusion, miR-141 was up-regulated in the biopsy samples and thus may be a potential biomarker for NPC in the Vietnamese population.
Highlights
Submitted: December 16, 2017 Accepted for publication: October 16, 2018 Last revision: November 05, 2018Nasopharyngeal carcinoma (NPC), which has pronounced differences in distribution according to geography and ancestry, is the fifth most common cancer worldwide
We found that among EBNA-1, EBNA-2, LMP-1 and LMP-2, at least one EBV DNA was detectable in 57.9% of nasopharyngeal carcinoma (NPC) samples, whereas a low frequency was found in non-cancerous swab samples.[13]
The NPC biopsy samples were confirmed as non-keratinizing squamous cell carcinoma and undifferentiated carcinoma via hematoxylin and eosin staining in histological examination (Figure 1)
Summary
Submitted: December 16, 2017 Accepted for publication: October 16, 2018 Last revision: November 05, 2018. Nasopharyngeal carcinoma (NPC), which has pronounced differences in distribution according to geography and ancestry, is the fifth most common cancer worldwide. NPC is present in 86,691 cases (age-standardized rate (ASR) = 1.2/100,000) and is responsible for 50,831 (ASR = 0.7/100,000) deaths annually in Vietnam.[1,2,3] patient diagnosis has improved in recent decades, most NPC patients are still diagnosed at an advanced stage of NPC, owing to ambiguous symptoms.[4,5,6] improved identification of potential biomarkers associated with NPC progression is essential for the development of new diagnosis strategies and promising therapies. The use of NPC biopsy samples is considered the “gold standard” in NPC diagnosis. Beside NPC biopsy samples, other types of samples, such as peripheral blood, nasopharyngeal swabs, throat swabs, plasma and
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
